Juvenescence Taps AI Guru, Expands to UAE for Longevity Push

ABU DHABI, UAE – February 16, 2026 – In a significant strategic maneuver, AI-enabled biotechnology company Juvenescence has announced the appointment of a new technology chief and a major operational expansion into the United Arab Emirates. The company has named Eileen Jennings-Brown, a veteran leader in life sciences technology, as its Chief Technology Officer while simultaneously establishing new research headquarters in Abu Dhabi’s Masdar City. The dual announcements signal a concerted effort to accelerate the discovery of longevity therapeutics by pairing advanced artificial intelligence with the UAE's burgeoning biotech ecosystem and unique genomic data resources.

A New AI Architect for an Ambitious Vision

The appointment of Eileen Jennings-Brown is a clear signal of Juvenescence’s intent to double down on its AI-driven strategy. With over 25 years of experience, Jennings-Brown brings a formidable track record from the intersection of technology and life sciences. She previously served as Chief Information Officer at Exscientia, an AI-powered precision medicine firm, where she was instrumental in shaping the technology strategy that supported its drug discovery platform. Before that, she held a senior technology leadership role at the prestigious Wellcome Trust, guiding its large-scale digital transformation.

Her role at Juvenescence will be to spearhead the global AI, data, and technology strategy, directly impacting the company's proprietary JuvAI platform. This platform is central to Juvenescence's mission to shorten development timelines and improve the success rate of drugs targeting the fundamental mechanisms of aging.

“Juvenescence offers a unique opportunity to combine my technical expertise and experience in the scientific research industry and data-driven precision medicine with the emerging field of longevity,” Jennings-Brown commented in the official announcement. “It's a rare chance to contribute to an area with such enormous potential and I am delighted to be joining the team.”

Dr. Richard Marshall, CEO of Juvenescence, highlighted the strategic importance of the hire. “Eileen brings exceptional expertise in building and scaling AI-driven technology platforms in biotech, having led technology transformation at Exscientia,” he stated. “Her deep understanding of how to harness computational power for drug discovery, combined with her track record of building world-class technical teams, will be instrumental as we expand our JuvAI platform capabilities in the UAE.”

The UAE's Emerging Biotech Oasis

Juvenescence's expansion is not just about a new office; it is a strategic embedment into one of the world's most ambitious life sciences hubs. The new facilities in Masdar City place the company at the heart of an ecosystem backed by significant government support, including initiatives from the Abu Dhabi Department of Health (DoH) and the Abu Dhabi Investment Office. This move aligns with the UAE's “Abu Dhabi Vision 2030,” which identifies life sciences as a cornerstone of its future diversified economy.

The expansion builds directly upon a strategic investment from M42, an Abu Dhabi-based global health leader, which was announced in April 2025. That partnership provided Juvenescence with significant capital and laid the groundwork for this deeper integration into the region. Masdar City is already home to other major players, including AI drug discovery firm Insilico Medicine, validating the region's appeal for cutting-edge biotech.

Juvenescence plans to build an Advanced AI Drug Discovery Laboratory in Masdar City to house its JuvAI platform. This move was welcomed by local partners. “The company’s focus on AI-enabled drug discovery and targeting fundamental aging mechanisms aligns strongly with Masdar City’s role as a home for life sciences companies,” said Marwan Mohamed, Business Development Manager for Life Sciences at Masdar City. “This collaboration reflects Abu Dhabi’s ambition to build a globally competitive biotechnology ecosystem.”

Unlocking the Code with Unprecedented Data

The most transformative aspect of Juvenescence's UAE expansion may be its access to unparalleled data resources. The company plans to leverage the Emirati Genome Project, a landmark initiative that has sequenced over 800,000 whole genomes, creating one of the largest and most valuable genomic datasets in the world. M42, Juvenescence's strategic partner, serves as the custodian of this data.

By applying its JuvAI platform to this vast repository of genomic and health information, Juvenescence aims to identify novel drug targets, develop precision biomarkers for aging, and accelerate patient selection for clinical trials. Access to the UAE's comprehensive healthcare infrastructure and diverse population is expected to dramatically shorten clinical trial timelines, a common bottleneck in drug development. This synergy between advanced AI and large-scale, high-quality human data is at the core of the company's new regional strategy.

Navigating a Crowded Field

Juvenescence operates in the increasingly competitive and well-funded longevity biotech sector, which is projected to become a market worth over $60 billion by 2026. The field includes titans like Altos Labs, backed by Jeff Bezos and focused on cellular rejuvenation, and AI pioneers like Insilico Medicine, which already has an AI-discovered drug in Phase 2 trials. Other companies like Unity Biotechnology are focused on senolytics—drugs that clear out aging cells—while Calico Life Sciences, a subsidiary of Google, investigates the fundamental biology of aging.

Against this backdrop, Juvenescence’s strategy appears to be one of integration and unique access. The company is not only developing its own AI platforms, enhanced by acquisitions like the June 2025 purchase of AI drug discovery firm Ro5 Inc., but is also building a diverse pipeline targeting cognition, cardio-metabolism, and immunity. By combining its proven drug development leadership, a sophisticated and fully integrated AI platform, and now exclusive access to a world-class data and clinical ecosystem in the UAE, Juvenescence is positioning itself to carve out a distinct and powerful advantage in the global race to extend healthy human lifespan.